These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 16708302)
1. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma. Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Ono K; Kubo S J Hepatobiliary Pancreat Surg; 2006; 13(3):239-44. PubMed ID: 16708302 [TBL] [Abstract][Full Text] [Related]
2. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281 [TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299 [TBL] [Abstract][Full Text] [Related]
4. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Morita T; Kikuchi T; Hashimoto S; Kobayashi Y; Tokue A Eur Urol; 1997; 32(2):237-44. PubMed ID: 9286660 [TBL] [Abstract][Full Text] [Related]
6. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Tseng CS; Lo HW; Chen PH; Chuang WL; Juan CC; Ker CG Hepatogastroenterology; 2004; 51(59):1454-8. PubMed ID: 15362775 [TBL] [Abstract][Full Text] [Related]
8. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897 [TBL] [Abstract][Full Text] [Related]
9. CYFRA 21-1 serum analysis in patients with esophageal cancer. Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239 [TBL] [Abstract][Full Text] [Related]
10. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
11. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck]. González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679 [TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy. Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861 [TBL] [Abstract][Full Text] [Related]
13. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer. Pavićević R; Milicić J; Bubanović G; Supe S Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620 [TBL] [Abstract][Full Text] [Related]
14. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A Lung; 2002; 180(5):273-9. PubMed ID: 12489021 [TBL] [Abstract][Full Text] [Related]
15. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649 [TBL] [Abstract][Full Text] [Related]
16. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783 [TBL] [Abstract][Full Text] [Related]
17. [Study on the relationship between serum cytokeratin 19 level in hepatocellular carcinoma patients and the clinico-pathologic characteristics]. Li Y; Tang ZY; Tian B; Qin LX; Ye SL; Sun RX Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):341-2. PubMed ID: 15225427 [TBL] [Abstract][Full Text] [Related]
18. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma. Lin WY; Yen TC; Cheng KY; Wang SJ Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997 [TBL] [Abstract][Full Text] [Related]
19. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409 [TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]